RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Allergan Inc.

A collection of news and information related to Allergan Inc. published by this site and its partners.

Top Allergan Inc. Articles

Displaying items 23-33
  • Botox-maker Allergan rejects takeover bid from Valeant

    Botox-maker Allergan Inc. said it rejected a takeover bid from Valeant Pharmaceuticals International Inc., a deal the company said undervalued its worth and posed significant risks to shareholders. Last month, the Irvine drugmaker received an...
  • Shire to acquire San Diego-based Lumena in more than $260 million deal

    Drug maker Shire is buying San Diego-based Lumena Pharmaceuticals for more than $260 million, a deal that expands the company's pipeline of rare disease treatments. The Irish company, producer of Adderall XR, plans to make a cash payment at the sale's...
  • Allergan rejects Valeant's takeover bid, but it's probably not over

    Botox maker Allergan Inc. rejected a $46-billion takeover offer from a Canadian rival, setting the stage for what analysts said may become a long and nasty fight for control of the Irvine company and its prized collection of eye and skin medications....
  • Valeant to increase bid for Allergan

    Valeant to increase bid for Allergan
    The stakes for Botox maker Allergan Inc. just got higher. Valeant Pharmaceutical International Inc. said it intends to raise its bid for Allergan, one day after the Irvine company defiantly rejected its initial offer as too low. In a letter to...
  • Ackman wants shareholders to push Allergan into takeover talks

    Activist investor Bill Ackman wants Allergan Inc. shareholders to vote on a resolution that would encourage the Botox maker to meet with its potential acquirer, Valeant Pharmaceuticals International Inc. In a filing Tuesday with the Securities and...
  • Valeant Pharmaceuticals vows to boost its $46-billion bid for Allergan

    The heated takeover fight over Allergan Inc., the maker of Botox, continued Tuesday with the Canadian pharmaceutical company Valeant vowing to increase its $46-billion offer this month. Meanwhile, the Canadian firm's partner in the offer, activist...
  • Zimmer to buy Biomet amid flurry of billion-dollar medical deals

    Zimmer to buy Biomet amid flurry of billion-dollar medical deals
    Orthopedic products maker Zimmer Holdings on Thursday announced it will acquire Biomet Inc. in a deal valued at $13.35 billion, including assumption of debt, the companies said.    The proposed acquisition follows a flurry of billion-dollar deals by...
  • Allergan employees have mixed emotions as layoffs loom

    Allergan employees have mixed emotions as layoffs loom
    Feelings were mixed among Allergan Inc. employees one day after the Botox maker announced 1,500 job cuts, mostly in Southern California. Outside of Allergan’s Irvine campus, where the bulk of the 650 research and development jobs the company...
  • The day ahead in business

    The day ahead in business
    Reports: Chicago Fed index of national economic activity Local earnings: Aptar Group Inc., Packaging Corp. of America Other earnings: Allergan Inc., Boise Cascade Co., Brown & Brown Inc., Hasbro Inc., Lennox International Inc., Rent-A-Center Inc., Six...
  • Most of Allergan's 1,500 job cuts will be in Southern California

    Most of Allergan's 1,500 job cuts will be in Southern California
    Most of the 1,500 job cuts that Botox maker Allergan Inc. announced Monday morning will be made in Southern California, the company’s chief executive said. Allergan plans to eliminate 650 research and development jobs, the bulk of them at its...
  • Allergan to slash workforce by 1,500

    Allergan to slash workforce by 1,500
    Botox maker Allergan Inc. said Monday that it will cut 1,500 employees, most of them in Southern California, in a cost-cutting effort the Irvine company hopes will help it fight off a hostile takeover bid by a Canadian rival. Stung by criticism that it'...